Cord Blood CD19-BCMA CAR-T Cell Therapy for Refractory Lupus Nephritis, Systemic Sclerosis, and Primary Sjogren's Syndrome with Pulmonary Hypertension
An investigator-initiated study at Beijing GoBroad Hospital evaluating an off-the-shelf, umbilical cord blood derived dual CD19-BCMA CAR-T cell therapy for patients with refractory lupus nephritis, systemic sclerosis, or primary Sjogren's syndrome with pulmonary arterial hypertension. CancerFax helps families review records, coordinate communication with the trial team, and understand whether this advanced cell therapy pathway may be relevant.
About This Clinical Trial
Systemic lupus erythematosus with lupus nephritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren's syndrome with pulmonary arterial hypertension (pSS-PAH) are severe autoimmune diseases driven by pathogenic autoantibodies. When patients do not respond well to steroids, conventional immunosuppressants, and biologics such as rituximab or belimumab, treatment options narrow quickly. Refractory lupus nephritis carries a high risk of progressive kidney damage. Systemic sclerosis leads to widespread fibrosis of the skin, lungs, heart, and kidneys. Sjogren's with pulmonary hypertension is rare, difficult to treat, and life-shortening.
This single-center, open-label, non-randomized, single-arm study at Beijing GoBroad Hospital is evaluating an investigational cell therapy: an allogeneic CAR-T product derived from healthy donor umbilical cord blood and engineered to target two markers at the same time, CD19 (on B cells) and BCMA (on antibody-producing plasma cells). The aim is to deeply deplete the cells responsible for producing harmful autoantibodies, allowing the immune system to reset.
Dual CD19 and BCMA targeting is scientifically significant in autoimmune disease because B-cell-only therapies often leave long-lived plasma cells untouched, and these cells continue producing pathogenic antibodies. Recent published work from Chinese centers has shown that co-targeting CD19 and BCMA can eliminate both populations, with early reports describing durable, drug-free remission in refractory lupus patients. Using umbilical cord blood as the cell source allows the product to be prepared in advance ('off-the-shelf'), reducing the wait time that autologous CAR-T manufacturing usually requires and potentially lowering manufacturing variability.
Early international experience with CAR-T in autoimmune disease, including separate Chinese single-arm trials of dual CD19-BCMA constructs and published case series of allogeneic CD19 CAR-T for severe SLE, has reported mostly low-grade cytokine release and no reported graft-versus-host disease so far. Long-term outcomes, durability of remission, and infection risk are still being characterised, and this is precisely what trials like NCT06947473 are designed to answer.
Whether an off-the-shelf, cord blood derived dual CD19-BCMA CAR-T can safely induce deep, durable disease control in patients with refractory SLE-LN, SSc, or pSS-PAH who have failed standard immunosuppression.
Trial at a Glance
A quick reference summary. This is a high-level overview only and not a confirmation of eligibility for any specific patient.
Final eligibility is determined only by the trial investigators after reviewing complete medical records.
Treatment Being Studied
The investigational therapy uses immune cells (T cells) prepared from healthy donor umbilical cord blood. In the laboratory, these cells are engineered to carry two chimeric antigen receptors (CARs) at the same time: one that recognises CD19 on B cells, and another that recognises BCMA on antibody-producing plasma cells.
When infused into a patient with refractory autoimmune disease, the modified cells are designed to find and destroy the B cells and plasma cells that produce the autoantibodies driving the disease. The intent is to reset the immune system so that, when new B cells return, they do so without the autoreactive memory that was driving organ damage.
How the therapy works (in simple terms)
In autoimmune diseases such as lupus, systemic sclerosis, and Sjogren's, certain B cells and long-lived plasma cells produce antibodies against the body's own tissues, leading to kidney inflammation, lung and skin fibrosis, or vascular damage. Standard immunosuppressants slow this down but do not always eliminate the cells driving it. By targeting both CD19 (B cells) and BCMA (plasma cells) at once, this CAR-T is designed for a deeper 'immune reset' than B-cell-only therapies. Because the cells come from umbilical cord blood from healthy donors, the product can be prepared in advance and given without the manufacturing wait that autologous CAR-T usually needs.
Full rheumatology evaluation, disease activity scoring (SLEDAI, mRSS, or ESSDAI as relevant), kidney biopsy review for SLE-LN, autoantibody panel, complement testing, organ function tests, infection screening, and confirmation that prior therapies have not produced adequate response.
Patient is admitted as an inpatient at Beijing GoBroad Hospital. Baseline assessments, supportive medications, and pre-treatment instructions are completed.
A short course of mild chemotherapy (commonly fludarabine and cyclophosphamide in cell therapy protocols; โ VERIFY exact regimen for this study) is given over a few days. The purpose is to make space in the immune system so the infused CAR-T cells can expand effectively.
The cord blood derived dual CD19-BCMA CAR-T product is administered as a one-time intravenous infusion. Because the product is allogeneic and prepared in advance, the wait is much shorter than autologous CAR-T.
Patients are monitored closely in hospital for cytokine release syndrome, infections, blood counts, and disease response. Supportive care, including tocilizumab for CRS if needed, is available on-site. Inpatient stay typically extends for several weeks after infusion.
After discharge, patients return for scheduled follow-up to assess disease activity (SLEDAI, organ-specific measures), B-cell return, autoantibody levels, immune reconstitution, and long-term safety. Long-term safety monitoring for cell therapy is typically advised for several years.
This cord blood CD19-BCMA CAR-T is not an approved treatment. It is being studied to assess safety and disease control. It should not be considered standard care, and outcomes cannot be predicted for any individual patient.
Who This Trial May Be For
This trial may be relevant for adults with severe, biopsy- or clinically-confirmed refractory autoimmune disease in one of the three studied indications, who have not adequately responded to standard immunosuppression and biologic therapy, and who are medically fit enough to undergo intensive monitoring after a one-time cell infusion.
Biopsy-confirmed proliferative lupus nephritis (ISN/RPS class III, IV, with or without V) with persistent activity, proteinuria, or worsening renal function despite standard induction therapy (steroids plus mycophenolate or cyclophosphamide) and, in many cases, at least one biologic such as rituximab or belimumab.
Diffuse cutaneous systemic sclerosis with rapidly progressive skin involvement (rising modified Rodnan skin score), early interstitial lung disease, or other major organ involvement that has not stabilised on standard immunosuppression.
Primary Sjogren's syndrome with confirmed pulmonary arterial hypertension that remains symptomatic or progressive despite PAH-directed therapy and immunosuppression.
Acceptable cardiac, hepatic, hematologic, and pulmonary reserve to tolerate lymphodepleting chemotherapy and one-time cell infusion. Active uncontrolled infection or end-stage organ failure typically excludes participation.
Patients require multidisciplinary review (rheumatology, nephrology or pulmonology, and cell therapy specialists). CancerFax can help organise records and coordinate this review with the trial team.
Patients and a primary caregiver must be willing to travel to Beijing, remain near Beijing GoBroad Hospital for the inpatient phase, and return for follow-up visits.
Eligibility Criteria
These criteria are derived from the trial registry entry and the standard pattern for CAR-T autoimmune protocols in China. They are illustrative. Meeting some criteria does not mean enrollment is confirmed โ the trial center makes the final decision after reviewing complete records.
check_circleInclusion Criteria โ May Be Eligible
- โAdults aged 18 years or older (โ VERIFY: maximum age from protocol โ commonly 65 or 70)
- โConfirmed diagnosis of one of: refractory lupus nephritis (SLE-LN) with biopsy-proven proliferative disease, systemic sclerosis (SSc) with active organ involvement, or primary Sjogren's syndrome with pulmonary arterial hypertension (pSS-PAH)
- โDocumented disease activity despite standard immunosuppressive therapy
- โInadequate response, intolerance, or contraindication to at least one biologic (such as rituximab or belimumab where applicable) (โ VERIFY: specific prior-therapy requirements)
- โAdequate cardiac, hepatic, renal, and pulmonary function as defined by the protocol
- โECOG performance status appropriate for cell therapy (typically 0-2; โ VERIFY)
- โNegative pregnancy test for women of childbearing potential, and agreement to use effective contraception
- โAbility and willingness to give informed consent and to comply with the trial schedule
cancelExclusion Criteria โ May Not Be Eligible
- รActive uncontrolled bacterial, viral, or fungal infection, including untreated HBV, HCV, HIV, or active tuberculosis
- รHistory of or active malignancy (with limited protocol-defined exceptions)
- รPrior CD19-, BCMA-, or other CAR-T or gene therapy (โ VERIFY exact prior cell-therapy rules)
- รSevere central nervous system involvement of the underlying disease (such as severe neuropsychiatric lupus)
- รEnd-stage kidney disease requiring dialysis (for SLE-LN candidates) or end-stage organ failure
- รActive autoimmune disease overlap requiring confounding therapy
- รPregnancy or breastfeeding
- รMajor surgery within a protocol-defined window before screening
- รAny medical or psychiatric condition that, in the investigator's judgement, makes the patient unsuitable for the study
Criteria here are illustrative. The trial protocol has its own detailed list. CancerFax can help organize records for review, but only the trial center can confirm participation.
Medical Records and Tests Needed for Review
Document quality is one of the most important factors in trial review. Complete, well-organised records help the trial team make a faster decision. CancerFax helps families compile, translate, and structure documents for submission.
How the Trial Process May Work
Cell therapy trials involve more steps than most rheumatology trials. The pathway below outlines what a patient and family can typically expect, from first contact to long-term follow-up.
CancerFax helps compile records and shares an anonymised case summary with Beijing GoBroad Hospital for preliminary assessment.
The trial team reviews disease activity, prior therapies, and organ function to indicate whether the patient may be a candidate.
On arrival in Beijing, the patient undergoes formal screening: physical examination, repeat autoantibody and disease activity assessments, imaging, infection screening, and protocol-specific tests.
The investigator team explains the trial in detail, including known risks, the experimental nature of the therapy, and what data will be collected. Consent is voluntary and can be withdrawn at any time.
Short lymphodepleting chemotherapy is given, followed by the one-time intravenous infusion of the cord blood CD19-BCMA CAR-T product.
Inpatient monitoring after infusion, then structured outpatient follow-up for disease activity, B-cell return, immune reconstitution, infections, and long-term safety, generally for several years.
Potential Benefits
Clinical trials in advanced cell therapy may offer access to investigational treatments not yet widely available. Benefits should always be considered alongside the risks and the realistic possibility that an individual patient may not respond.
Cord blood derived dual CD19-BCMA CAR-T is not an approved or widely available treatment. This trial offers structured access under research oversight at one of China's research-focused hospitals.
Because the cells come from healthy donor cord blood, the product is prepared in advance. This reduces the wait time compared with autologous CAR-T, which can matter for patients with rapidly progressive disease.
Targeting CD19 and BCMA together is intended to clear both B cells and plasma cells, addressing a key limitation of B-cell-only therapies in autoimmune disease.
Patients are managed by a team experienced in cell therapy, with on-site monitoring for cytokine release syndrome, infections, and other cell therapy specific complications.
Trial protocols typically require more frequent assessments than routine care, which can mean earlier detection of any change in disease activity or side effects.
Outcomes from this study help define the role of allogeneic CAR-T in autoimmune diseases, an emerging field where data is still limited globally.
Cell therapy in autoimmune disease is early-stage. A trial may or may not directly benefit an individual patient, and durability of response is still being studied. Realistic expectations are essential.
Risks and Side Effects
Every cell therapy trial carries risks specific to the therapy class. The risks below reflect what has been described for CD19-, BCMA-, and dual CD19-BCMA CAR-T in autoimmune disease and in oncology, plus the additional considerations of an allogeneic cord blood derived product.
An inflammatory reaction that can cause fever, low blood pressure, and breathing difficulty. Published reports of CD19-BCMA CAR-T in SLE describe mostly grade 1 CRS that resolves with supportive care including tocilizumab. Severe CRS is uncommon in autoimmune CAR-T to date, but cannot be ruled out.
Lymphodepleting chemotherapy causes a drop in white cells, platelets, and red cells. This raises infection and bleeding risk for several weeks and requires close monitoring, transfusion support if needed, and prophylactic anti-infectives.
Deep B-cell and plasma-cell depletion can lead to low antibody levels for months, increasing the risk of bacterial and viral infections. Immunoglobulin replacement may be required, and reactivation of viruses such as CMV, EBV, or hepatitis B is possible.
Immune effector cell associated neurotoxicity syndrome can cause confusion, tremor, speech changes, or seizures. ICANS appears uncommon in published autoimmune CAR-T experience but remains a recognised CAR-T class risk.
Because the cells come from an unrelated donor (cord blood), graft-versus-host disease and host rejection of the product are theoretical risks. Cord blood CAR-T has so far reported a low GvHD rate, but this is a key safety question the trial is designed to answer.
Long-term effects of dual CD19-BCMA CAR-T in autoimmune disease, including durability of remission, late infections, secondary malignancy, and reproductive impact, are not yet fully characterised.
Time and travel burden, no guarantee of disease control, possible trial discontinuation, and the cost of staying near Beijing for monitoring should be weighed carefully with the family and treating rheumatology team.
Trial Location and Hospital Information
This is a single-center study based at Beijing GoBroad Hospital in Changping District, Beijing. The hospital is one of China's research-focused centers with a dedicated Phase I clinical trial unit and significant experience in CAR-T cell therapy, with multilingual support services for international patients available through GoBroad Healthcare Group.
International patients typically require: an S2 or M medical visa, professionally translated medical records and imaging reports, remote preliminary review by the trial team, accommodation arrangements near the hospital for the inpatient and immediate follow-up period, and a primary caregiver present throughout treatment. CancerFax coordinates record translation, secure submission to the hospital, communication during preliminary review, and on-ground logistics support.
Costs, Trial Coverage, and Patient Expenses
Costs in investigator-initiated cell therapy trials in China vary case by case. The investigational product itself is often partially or fully covered by the sponsoring hospital or sponsor, while hospital admission, supportive care, complications, and travel are generally the patient's responsibility. All cost details must be confirmed in writing by the trial center before any commitment.
CancerFax helps understand the expected cost categories and what is covered. Final confirmation must come from Beijing GoBroad Hospital in writing before any travel or financial commitment.
Standard Treatment vs Clinical Trial
Standard immunosuppression and biologic therapy remain the foundation of care for SLE, SSc, and Sjogren's syndrome. Cell therapy is an investigational option for patients whose disease remains active despite these treatments. The table below highlights how a clinical trial pathway differs from standard care.
How CancerFax Helps Patients Explore This Trial
CancerFax is a specialist patient-navigation platform focused on advanced cell therapy, gene therapy, and complex cross-border treatment access. For autoimmune cell therapy trials in China, our role is to organise the case, coordinate communication with the trial center, and help families understand the realistic pathway, costs, and risks.
Structured review of diagnosis, biopsy reports, autoantibody panel, disease activity scores, prior therapies, and organ function.
Preparing an anonymised case summary and submitting it to the Beijing GoBroad Hospital trial team for preliminary review.
Coordinating questions, follow-up requests, and document submission between the patient's local team and the trial investigators.
Visa guidance, translated record preparation, accommodation suggestions near the hospital, and pre-admission logistics.
If this trial is not a fit, helping explore alternative cell therapy trials, biologic options, or advanced rheumatology consultation pathways.
From initial inquiry to follow-up after discharge, a single point of contact through CancerFax's patient services team.
CancerFax does not guarantee trial enrollment, treatment response, or outcome. Our role is to help patients access accurate information and appropriate pathways.
Questions to Ask Before Considering This Trial
These questions can help families have a more informed discussion with the trial team and with the patient's rheumatologist before deciding on travel or participation.
Frequently Asked Questions
Want to Know Whether This Trial May Be Relevant?
CancerFax can review the case, organise the documents, and coordinate with Beijing GoBroad Hospital to find out whether a patient with refractory SLE-LN, SSc, or pSS-PAH may be considered for this cord blood CD19-BCMA CAR-T study.
The information on this page is for educational and patient-navigation purposes only. It does not replace medical advice, diagnosis, or treatment from a qualified physician. Clinical trial eligibility, enrollment, treatment decisions, and costs are determined only by the trial investigators, hospital, sponsor, and applicable regulations. CancerFax helps patients and families understand options and coordinate case review where appropriate, but does not guarantee trial acceptance, treatment response, or clinical outcome. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.
Explore Related CancerFax Pages
ยฉ CancerFax ยท Specialist cancer access and patient-navigation platform. CancerFax is not a medical institution, hospital, or clinical trial sponsor. Trial details may change; always confirm current eligibility, status, and costs directly with the trial center.